No Data
Hong Kong biotech stocks plummeted intraday. Kangfang Biotech fell nearly 23%, BeiGene Shenzhou fell more than 6.5%, and Zaiding Pharmaceuticals and Kingsley Biotech all fell more than 5.5%.
Hong Kong biotech stocks plummeted intraday. Kangfang Biotech fell nearly 23%, BeiGene Shenzhou fell more than 6.5%, and Zaiding Pharmaceuticals and Kingsley Biotech all fell more than 5.5%.
Zai Lab Doses First Subject in Phase II Plaque Psoriasis Treatment Trial
Express News | Zaiding Pharmaceutical: ZL-1102 has not been approved in China to treat chronic plaque psoriasis
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai's global capabilities Based on a proof-of-concept study, ZL-1102 is the first topical biologic to
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+